title: FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
abstract: FLT3: gene alterations (internal tandem duplications - ITDs - and D835 mutations) are thought to be associated with poor-risk acute myeloid leukemia (AML). However, not all studies confirm this association, so it is still a matter of debate. Moreover, their association with other molecular abnormalities is less studied. We have investigated the presence of FLT3-ITD and D835 mutations in AML patients and their correlation with clinical and biological disease characteristics. The presence of ITD was analyzed in diagnostic samples of 176 AML patients and the D835 mutation in 135 of these patients. In all these patients, the presence of four well-known molecular abnormalities were also simultaneously characterized: PML/RARalpha, AML1/ETO, CBFbeta/MYH11 and MLL rearrangements. In all, 41 (23%) patients harbored FLT3 mutations, with 34 (19.3%) of them positive for the ITD, and seven (5%) positive for the D835 mutation. Of the acute promyelocytic leukemia (APL) patients, 16 (27%) showed FLT3 mutations, more frequently in M3 hypogranular cases (62% versus 17%, P=0.001) and cases with the short (bcr3) PML-RARalpha isoform (69%, P=0.002). In contrast, FLT3 was never altered in patients with inv(16), t(8;21) or 11q23 abnormalities. FLT3 mutations were significantly associated with some negative prognostic features at diagnosis (leukocytosis, high blast-cell percentage, and elevated LDH values), but they were not associated with different disease-free or overall survival. Therefore, we confirm a high frequency of FLT3 mutations in APL and in adult AML without recurrent cytogenetic translocations. In addition, they were not found as independent prognostic factors although associated with several adverse features at diagnosis.
authors.affiliation: Hematology Department, University Hospital of Salamanca, Salamanca, Spain.
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Chillón
authors.forename: Carina
authors.initials: C
authors.lastname: Fernández
authors.forename: Ramón
authors.initials: R
authors.lastname: García-Sanz
authors.forename: Ana
authors.initials: A
authors.lastname: Balanzategui
authors.forename: Fernando
authors.initials: F
authors.lastname: Ramos
authors.forename: Javier
authors.initials: J
authors.lastname: Fernández-Calvo
authors.forename: Marcos
authors.initials: M
authors.lastname: González
authors.forename: Jesús F San
authors.initials: JF
authors.lastname: Miguel
mesh_terms: D000208:Acute Disease; D000328:Adult; D001483:Base Sequence; D002877:Chromosomes, Human / Q000235:genetics; D017931:DNA Primers; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D011956:Receptors, Cell Surface / Q000235:genetics; D015203:Reproducibility of Results; D016019:Survival Analysis; D017741:Survivors; D013997:Time Factors; D014178:Translocation, Genetic / Q000235:genetics; D051941:fms-Like Tyrosine Kinase 3
chemical_list: D017931:DNA Primers; D011518:Proto-Oncogene Proteins; D011956:Receptors, Cell Surface; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3